Last reviewed · How we verify
Candemore tablet
Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure.
Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure. Used for Essential hypertension, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Candemore tablet |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The drug binds to angiotensin II type 1 (AT1) receptors on vascular smooth muscle and other tissues, preventing angiotensin II-mediated vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. ARBs like candesartan (the active ingredient) are commonly used as first-line agents for hypertension management.
Approved indications
- Essential hypertension
- Heart failure with reduced ejection fraction
Common side effects
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
- Cough
Key clinical trials
- A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (PHASE4)
- To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure (PHASE4)
- The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candemore tablet CI brief — competitive landscape report
- Candemore tablet updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI